Close Menu

NEW YORK – GenScript Biotech Europe announced on Tuesday that it received the CE-IVD mark for its test for detecting antibodies against SARS-CoV-2.

The cPass-SARS-CoV-2 Surrogate Virus Neutralization Test will be sold as an in vitro diagnostic kit, the Leiden, Netherlands-based firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.